ArticleBMC microbiology2025
FabG moonlights as an extracellular adhesin mediates cytoadhesion of Streptococcus suis via interaction with plasminogen.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathogenicity and virulence ofVirulence · 2026Review
- The truncated major pilin subunit SBP2' contributes toApplied and environmental microbiology · 2026Article
- Class C sortases of the SrtBCD pilus cluster involved in the virulence of Streptococcus suis in the mouse model.Folia microbiologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Streptococcus suis serotype 2 (SS2) is an important zoonotic bacterial pathogen that can causes meningitis, septicemia, endocarditis, arthritis, pneumonia, and streptococcal toxic shock-like syndrome in pigs and humans. FabG, an essential reductase in the bacteria type II fatty acid synthesis pathway, is present in the extracellular space and binds to many extracellular matrix components of the host. In this study, we investigated the moonlight function of FabG. First, we found that the transcription of FabG in virulent SS2 strains was significantly higher than in avirulent strains, indicating that FabG may be involved in the pathogenesis of S. suis. After preparation of recombinant proteins, we found that the recombinant FabG could directly bind to host epithelial cells. ELISA, SPR, and Far-Western blot assays showed that rFabG could bind to the host plasminogen. Furthermore, the ability of rFabG to recruit host plasminogen to degrade the host ECM component was visualized by electron microscopy. Moreover, we found that rFabG could bind to complement C3 in serum and enhance the survival ability of S. suis in serum. Collectively, these data imply that FabG is a moonlight adhesin involved in S. suis cytoadhesion and a plasminogen receptor that could help S. suis break through the host barrier or evade immune defenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.